Tislelizumab, a programmed cell death-1 (PD-1) inhibitor, is approved in China for the treatment of classical Hodgkin lymphoma, lung cancer, hepatocellular carcinoma, and other malignancies (4). This evidence concerns the gene PDCD1 and Hodgkins lymphoma.